Evaluation of Hi-C sequencing for the detection of gene fusions in hematologic and solid pediatric cancer samples
Preprint
Abstract
HiC sequencing is a DNA-based next-generation sequencing method that preserves the 3D conformation of the genome and has shown promise in detecting genomic rearrangements in translational research studies. To evaluate HiC as a potential clinical diagnostic platform, analytical concordance with routine laboratory testing was assessed using primary pediatric leukemia and sarcoma specimens previously positive for clinically significant genomic rearrangements. Archived specimen types tested included viable and nonviable frozen leukemic cells, as well as formalin-fixed paraffin-embedded (FFPE) tumor tissues. Initially, pediatric acute myeloid leukemia (AML) and alveolar rhabdomyosarcoma (A-RMS) specimens with known genomic rearrangements were subjected to HiC analysis to assess analytical concordance. Subsequently, a discovery cohort consisting of AML and acute lymphoblastic leukemia (ALL) cases with no known genomic rearrangements based on prior clinical diagnostic testing were evaluated to determine whether HiC could detect rearrangements. Using a standard sequencing depth of 50 million raw read-pairs per sample, or approximately 5X raw genomic coverage, 100% concordance was observed between HiC and previous clinical cytogenetic and molecular testing. In the discovery cohort, a clinically relevant gene fusion was detected in 45% of leukemia cases (5/11). This study demonstrates the value of HiC sequencing to medical diagnostic testing as it identified several clinically significant rearrangements, including those that might have been missed by current clinical testing workflows. Key points HiC sequencing is a DNA-based next-generation sequencing method that preserves the 3D conformation of the genome, facilitating detection of genomic rearrangements. HiC was 100% concordant with clinical diagnostic testing workflows for detecting clinically significant genomic rearrangements in pediatric leukemia and rhabdomyosarcoma specimens. HiC detected clinically significant genomic rearrangements not previously detected by prior clinical cytogenetic and molecular testing. HiC performed well with archived non-viable and viable frozen leukemic cell samples, as well as archived formalin-fixed paraffin-embedded tumor tissue specimens.Keywords
This publication has 42 references indexed in Scilit:
- Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspectiveCell, 2024
- Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1)Pediatric Blood & Cancer, 2023
- Optical genome mapping for structural variation analysis in hematologic malignanciesAmerican Journal of Hematology, 2022
- Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcriptionCancer Cell, 2021
- Maintaining a methods database to optimize solid tumor tissue culture: Review of a 15-year database from a single institutionCancer Genetics, 2019
- Acute leukemias harboring KMT2A/MLLT10 fusion: a 10‐year experience from a single genomics laboratoryGenes, Chromosomes and Cancer, 2019
- Juicebox Provides a Visualization System for Hi-C Contact Maps with Unlimited ZoomCell Systems, 2016
- Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C ExperimentsCell Systems, 2016
- Genome-wide arrays in routine diagnostics of hematological malignanciesHuman Mutation, 2012
- Formalin-Fixed and Paraffin-Embedded Tissue Sections2002